Kepos Capital’s Elevance Health ELV Stock Holding History

Kepos Capital’s Portfolio ELV Stock Details ELV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-9,432	Closed	-$2.25M	–	367
2018 Q2	$2.25M	Buy	+9,432	New	+$2.18M	0.11%	154
2018 Q1	–	Sell	-20,012	Closed	-$4.5M	–	298
2017 Q4	$4.5M	Buy	20,012 +16,128	+415%	+$3.44M	0.41%	55
2017 Q3	$737K	Buy	+3,884	New	+$739K	0.12%	66

Other funds holding ELV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Kepos Capital's ELV Position: Q3 2018 in Review

Kepos Capital sold out of Elevance Health (ELV) in Q3 2018, closing a stake of 9,432 shares — an estimated $2.25M sold.

Kepos Capital first reported a position in ELV in Q3 2017 and held it in 3 quarters. The position peaked at $4.5M in Q4 2017. 945 funds tracked by Wall St. Rank hold ELV as of Q3 2018.

Kepos Capital reported no remaining Elevance Health position as of Q3 2018 after selling out during the quarter.
Kepos Capital sold 9,432 Elevance Health shares in Q3 2018, an estimated $2.25M.
Kepos Capital first reported a position in Elevance Health in Q3 2017 and held it in 3 quarters.
Kepos Capital's Elevance Health position peaked at $4.5M in Q4 2017.
945 funds tracked by Wall St. Rank held Elevance Health as of Q3 2018.

Based on Kepos Capital's 13F filing for Q3 2018, filed 13 Nov 2018.